Search Results 461-470 of 16620 for alopecia

1. A Study to Evaluate AVID200 in Myelofibrosis Patients - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia. Women of child bearing potential (WCBP), defined ...

2. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma - Mayo Clinic

   0) Grade -study baseline (except alopecia or neuropathy); Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST ...

3. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma - Mayo Clinic

   The following are exceptions to this criterion: subjects with vitiligo or alopecia; subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable ...

4. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   ... alopecia. Patients with clinical signs of central nervous system (CNS) involvement of MM. Patients with known or suspected light chain amyloidosis of any ...

5. A Study to Evaluate Rectal Cancer with Diffusion-Weighted and Dynamic Contrast Enhanced Perfusion-Weighted Magnetic Resonance Imaging - Mayo Clinic

   The purpose of this study is to analyze the apparent diffusion coefficient (ADC) from Diffusion-Weighted (DWI) in patients before, during the second week of and ...

6. A Study to Evaluate the Safety and Effectiveness of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer - Mayo Clinic

   With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment;; Spinal cord ...

7. Betamethasone and calcipotriene (topical application route) - Mayo Clinic

   Betamethasone is a corticosteroid (cortisone-like medicine or steroid). It helps relieve redness, pain, itching, swelling, or other discomfort caused by certain ...

8. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...

9. Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) - Mayo Clinic

   Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤ 1 or baseline.

10. Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma - Mayo Clinic

    Note: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study. Note: If patients ...